Unicycive Therapeutics Amends ATM Program, Reports $11.2M in Recent Stock Sales, and Files $150M Universal Shelf

summarizeSummary

Unicycive Therapeutics filed a $150 million universal shelf registration and amended its ATM program to $50 million, reporting recent sales of $11.2 million in common stock. This provides critical liquidity but signals significant potential dilution for shareholders.

check_boxKey Events

• New Universal Shelf Registration

  The company filed an S-3 registration statement for a universal shelf, allowing it to offer and sell various securities (common stock, preferred stock, debt, warrants, units) with an aggregate initial offering price of up to $150 million from time to time.

• Amended At-The-Market (ATM) Program

  The existing Sales Agreement with Guggenheim Securities, LLC, originally dated November 13, 2024, was further amended on June 5, 2026, increasing the capacity for at-the-market sales of common stock to a maximum aggregate offering price of $50 million.

• Reported Recent Stock Sales

  Subsequent to March 31, 2026, the company sold 1,693,000 shares of common stock at an average price of $7.34 per share, resulting in net proceeds of approximately $11.2 million. This represents about 6.18% dilution based on current outstanding shares.

• Capital for General Corporate Purposes

  Proceeds from the offering are intended for general corporate purposes, including product development and commercialization, research and development, general and administrative expenses, and working capital.

auto_awesomeAnalysis

Unicycive Therapeutics has filed a universal shelf registration statement for up to $150 million in various securities, including common stock, preferred stock, debt, warrants, and units. Concurrently, the company amended its At-The-Market (ATM) Sales Agreement, increasing the program's capacity to $50 million. Critically, the filing discloses that subsequent to March 31, 2026, the company already sold 1,693,000 shares of common stock at an average price of $7.34 per share, generating approximately $11.2 million in net proceeds. This represents a significant capital raise for the company, equivalent to about 6.18% dilution based on current outstanding shares, and the full $50 million ATM program could result in approximately 24.57% dilution. This financing activity provides essential liquidity following a widened net loss in Q1 2026 and ahead of a crucial FDA PDUFA date of June 29, 2026, for its OLC drug, but also introduces substantial potential dilution for existing shareholders.